Overview

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
Phase:
Phase 1
Details
Lead Sponsor:
Respirent Pharmaceuticals Co Ltd.
Collaborator:
Becro Ltd.
Treatments:
Fluticasone
Fluticasone-Salmeterol Drug Combination
Salmeterol Xinafoate
Xhance